In amongst a clutch of discontinued phase 3 programmes in ... candidate zinpentraxin alfa (PRM-151) and a phase 1 study of efmarodocokin alfa in acute graft versus host disease (GVHD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback